menu
    • menu
    [{"orgOrder":0,"company":"MiMedx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Purion Processed Dehydrated Human Amnion\/Chorion Membrane","moa":"TGF beta1","graph1":"Dermatology","graph2":"Preclinical","graph3":"MiMedx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"MiMedx \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"MiMedx \/ Not Applicable"},{"orgOrder":0,"company":"MiMedx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Micronized Dehydrated Human Amnion Chorion Membrane","moa":"","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"MiMedx","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"MiMedx \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"MiMedx \/ Not Applicable"},{"orgOrder":0,"company":"MiMedx","sponsor":"U.S. Army Medical Research and Development","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Funding","leadProduct":"Dehydrated Human Amnion Chorion Membrane","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"MiMedx","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"MiMedx \/ U.S. Army Medical Research and Development","highestDevelopmentStatusID":"1","companyTruncated":"MiMedx \/ U.S. Army Medical Research and Development"},{"orgOrder":0,"company":"MiMedx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Human Amnion Membrane Allograft","moa":"","graph1":"Podiatry","graph2":"Approved","graph3":"MiMedx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"","sponsorNew":"MiMedx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MiMedx \/ Not Applicable"},{"orgOrder":0,"company":"MiMedx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Acellular Human Extracellular Matrix","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MiMedx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Lotion","sponsorNew":"MiMedx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MiMedx \/ Not Applicable"},{"orgOrder":0,"company":"MiMedx","sponsor":"Gunze Medical Limited","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"Human Amnion Membrane Allograft","moa":"","graph1":"Podiatry","graph2":"Approved","graph3":"MiMedx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"","sponsorNew":"MiMedx \/ Gunze Medical Limited","highestDevelopmentStatusID":"12","companyTruncated":"MiMedx \/ Gunze Medical Limited"},{"orgOrder":0,"company":"MiMedx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Lyophilized Human Placental-based Allograft","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MiMedx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"MiMedx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MiMedx \/ Not Applicable"},{"orgOrder":0,"company":"MiMedx","sponsor":"MediWound","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"","graph1":"Podiatry","graph2":"Preclinical","graph3":"MiMedx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"MiMedx \/ MediWound","highestDevelopmentStatusID":"4","companyTruncated":"MiMedx \/ MediWound"}]

    Find Clinical Drug Pipeline Developments & Deals by MiMedx

    Menu

    MiMedx

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            MiMedx

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            MiMedx

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lyophilized Human Placental-based Allograft

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            MIMEDX Announces Launch of EPIEFFECT

                            Details : EPIEFFECT is a lyophilized human placental-based allograft consisting of amnion and chorion membranes, while also retaining the intermediate layer. EPIEFFECT is intended for use as a barrier, to provide a protective environment in acute and chronic wound...

                            Brand Name : Epieffect

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            September 26, 2023

                            Lead Product(s) : Lyophilized Human Placental-based Allograft

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            MiMedx

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            MiMedx

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bromelain Enriched Proteolytic Enzyme,Dehydrated Human Amnion Membrane

                            Therapeutic Area : Podiatry

                            Study Phase : Preclinical

                            Sponsor : MediWound

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            MediWound Announces Collaboration with MIMEDX on EscharEx® Phase III Study

                            Details : Under the collaboration, MIMEDX will provide its market leading placental tissue allograft EPIFIX® to be used during the wound healing phase of the EscharEx® (concentrate of proteolytic enzymes enriched in bromelain) Phase III study in venous leg ulcer...

                            Brand Name : EscharEx

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            August 15, 2023

                            Lead Product(s) : Bromelain Enriched Proteolytic Enzyme,Dehydrated Human Amnion Membrane

                            Therapeutic Area : Podiatry

                            Highest Development Status : Preclinical

                            Sponsor : MediWound

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            MiMedx

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            MiMedx

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Human Amnion Membrane Allograft

                            Therapeutic Area : Podiatry

                            Study Phase : Approved

                            Sponsor : Gunze Medical Limited

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            MIMEDX Announces Commercial Launch of EPIFIX® in Japan with Exclusive Distribution Agreement with Gunze Med...

                            Details : EPIFIX (human amnion membrane allograft) is a PURION® processed placental tissue allograft that supports the healing cascade by providing a semi-permeable, protective barrier over wounds.

                            Brand Name : Epifix

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            January 04, 2023

                            Lead Product(s) : Human Amnion Membrane Allograft

                            Therapeutic Area : Podiatry

                            Highest Development Status : Approved

                            Sponsor : Gunze Medical Limited

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            MiMedx

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            MiMedx

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Acellular Human Extracellular Matrix

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            MIMEDX Announces Launch of AXIOFILL™

                            Details : AXIOFILL is an acellular human extracellular matrix (ECM) derived from the placental disc. AXIOFILL preserves multiple ECM components and other matrix-bound proteins and is intended for use in the replacement or supplementation of damaged or inadequate i...

                            Brand Name : Axiofill

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 20, 2022

                            Lead Product(s) : Acellular Human Extracellular Matrix

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            MiMedx

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            MiMedx

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Human Amnion Membrane Allograft

                            Therapeutic Area : Podiatry

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            MIMEDX EPIFIX® Receives Reimbursement Approval in Japan

                            Details : EPIFIX (Human Amnion-chorion Membrane Allograft) is a PURION® processed placental tissue allograft that supports the healing cascade by providing a protective barrier over wounds.

                            Brand Name : Epifix

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            September 12, 2022

                            Lead Product(s) : Human Amnion Membrane Allograft

                            Therapeutic Area : Podiatry

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            MiMedx

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            MiMedx

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dehydrated Human Amnion Chorion Membrane

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Undisclosed

                            Sponsor : U.S. Army Medical Research and Development

                            Deal Size : $4.6 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            MIMEDX Receives $4.6 Million Award from the Department of Defense to Advance the Treatment of Combat Casualty ...

                            Details : The award will be used to advance the clinical understanding of PURION® processed Dehydrated Human Amnion Chorion Membrane, specifically in treating acute injuries and preventing initially partial-thickness burns from deteriorating to full-thickness bur...

                            Brand Name : DHACM

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            May 31, 2022

                            Lead Product(s) : Dehydrated Human Amnion Chorion Membrane

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Undisclosed

                            Sponsor : U.S. Army Medical Research and Development

                            Deal Size : $4.6 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            MiMedx

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            MiMedx

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Micronized Dehydrated Human Amnion Chorion Membrane

                            Therapeutic Area : Musculoskeletal

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Two New Studies Demonstrate In Vitro Bioactivity Potential of Micronized Dehydrated Human Amnion Chorion Membr...

                            Details : Data show mdHACM mitigates effects of inflammatory-induced degeneration in chondrocytes, the Primary Cell Type in Cartilage. These results further support mdHACM as an investigational new drug candidate for the treatment of OA and highlight potential dis...

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            November 01, 2021

                            Lead Product(s) : Micronized Dehydrated Human Amnion Chorion Membrane

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            MiMedx

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            MiMedx

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Purion Processed Dehydrated Human Amnion/Chorion Membrane

                            Therapeutic Area : Dermatology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            New Study Demonstrates Potential for MIMEDX Purion® Processed Dehydrated Human Amnion / Chorion Membrane

                            Details : MIMEDX Purion processed dHACM has been used extensively for the treatment of multiple acute and chronic conditions ranging from diabetic foot ulcers and significant burn injuries to musculoskeletal and sports medicine applications.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            June 15, 2021

                            Lead Product(s) : Purion Processed Dehydrated Human Amnion/Chorion Membrane

                            Therapeutic Area : Dermatology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth